Gastroenterology
Latest News
June 17th 2025
Using FMT over standard-of-care therapy may significantly reduce antibiotic use and well-known harms, including antibiotic resistance, study authors noted.
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
View More
GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer
View More
Oncology Town Hall™ 2025 ESMO-GI Congress Highlights: The Latest Data on Immune-Based Strategies Across Hepato...
July 15, 2025
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Burst CME™: Future Implications for the Treatment Landscape of Primary Biliary Cholangitis (PBC)
View More
Burst CME™: Reimagining Approaches to Treating Patients with Primary Biliary Cholangitis (PBC)
View More
Burst CME™: Enhancing Strategies for Diagnosing Primary Biliary Cholangitis (PBC)
View More
Medical Crossfire: Individualizing Treatment Plans in Advanced Hepatocellular Carcinoma Based on Biology and Other Patient Characteristics
View More
2025 International Symposium of Gastrointestinal Oncology (ISGIO)
September 12-13, 2025
Register Now!
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
Community Practice Connections™: Individualizing Treatment Plans in Advanced Hepatocellular Carcinoma Based on Biology and Other Patient Characteristics
View More
Collaborating Across the Continuum™: Identifying and Preventing Hepatic Encephalopathy in Long-Term Care Settings
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?
View More
(CME Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention
View More
(COPE Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention
View More
Community Practice Connections™: 21st Annual Meeting of the International Society of Gastrointestinal Oncology
View More
42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow
View More
Molecular Testing and Personalized Strategies in Pancreatic Cancer: Targeting NRG1 and Rare Drivers With an Optimized Approach
View More
Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers
View More
Addressing Unmet Needs in HER2+ Metastatic BTC
View More
The Role of the Multidisciplinary Care Team in the Diagnosis and Management of Acute Hepatic Porphyria
View More
10th Annual School of Gastrointestinal Oncology
View More
From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment
View More
Proactive Adverse Event Management for HER2+ BTC Treatments
View More
More News
Irritable Bowel Syndrome: Rational Therapy
January 1st 2007ABSTRACT: Irritable bowel syndrome (IBS) is characterized by abdominal pain or discomfort, bloating, and constipation or diarrhea; the pain is typically relieved by defecation. The diagnosis is not one of exclusion; it can be made based on the answers to a few key questions and the absence of "alarm" symptoms. Fiber therapy, the elimination of particular foods, and regulation of bowel function can help relieve symptoms. Tegaserod or polyethylene glycol can be used to treat IBS with constipation. Loperamide and alosetron are of benefit in IBS with diarrhea (although the latter carries a small risk of ischemic colitis). Low-dose tricyclic antidepressants may be used to treat the abdominal pain associated with IBS. Probiotic therapy or rifaximin may help reduce bloating. Psychological therapies seem to improve well-being in patients with IBS.
